Drug Monographs: Ixazomib and Necitumumab

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

[1]  A. Hui,et al.  Abstract B147: A phase 1 drug-drug interaction study between ixazomib, an oral proteasome inhibitor, and rifampin in patients (pts) with advanced solid tumors , 2015 .

[2]  D. Esseltine,et al.  Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study , 2015, Journal of Hematology & Oncology.

[3]  A. Dispenzieri,et al.  Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib , 2015, Blood Cancer Journal.

[4]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[5]  David C. Smith,et al.  Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies , 2015, Investigational New Drugs.

[6]  C. Schumann,et al.  Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. , 2015, The Lancet. Oncology.

[7]  Neeraj Gupta,et al.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. , 2014, The Lancet. Oncology.

[8]  Michael L. Wang,et al.  Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. , 2014, Blood.

[9]  A. Hui,et al.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. , 2014, Blood.

[10]  K. Venkatakrishnan,et al.  A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma. , 2013 .

[11]  A. Hui,et al.  MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study , 2012 .

[12]  Sudip K. Das.  Clinical Pharmacology and Biopharmaceutics , 2012 .

[13]  A. Hui,et al.  Weekly Dosing of the Investigational Oral Proteasome Inhibitor MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From a Phase 1 Dose-Escalation Study , 2011 .

[14]  K. Venkatakrishnan,et al.  Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies , 2011 .

[15]  G. Giaccone,et al.  A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies , 2010, Clinical Cancer Research.